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ABSTRACT
Background There is significant interest in determining 
risk factors in individuals at risk of rheumatoid arthritis 
(RA). A core set of risk factors for clinical arthritis 
development has not been defined.
Methods A literature search and systematic literature 
review (SLR) was conducted to identify risk factors in 
individuals at risk of RA using Medline, Embase, PubMed 
and Central databases.
Results 3854 articles were identified by the literature 
search. After screening of titles, 138 abstracts were 
reviewed and 96 articles finally included. Fifty- 
three articles included data on risk factors including 
autoantibodies, subclinical inflammation on imaging, 
clinical features, serum and cellular biomarkers and 
genetic markers. Risk factors were dependent on the 
at- risk population. There was good evidence for serum 
anticitrullinated protein antibodies (ACPA) levels, as 
risk factors for arthritis in all at- risk populations (n=13 
articles). Subclinical inflammation on ultrasound (n=12) 
and MRI (n=6) was reported as a risk factor in multiple 
studies in at- risk individuals with musculoskeletal 
(MSK) symptoms and undifferentiated arthritis (UA). 
Clinical features were reported as a risk factor in at- risk 
individuals with MSK symptoms and UA (n=13). Other risk 
factors, including serum and cellular markers were less 
frequently reported.
Conclusions Risk factors for arthritis development in RA 
are specific to the at- risk population. Serum ACPA confers 
risk in all populations; subclinical inflammation on imaging 
and clinical features confer risk in at- risk individuals with 
MSK symptoms. This SLR informed the EULAR taskforce 
for points to consider on conducting clinical trials and 
studies in individuals at risk of RA.
INTRODUCTION
Furthering our understanding of the preclin-
ical phase of rheumatoid arthritis (RA) is 
likely to hold the key to disease prevention. 
The identification, follow- up and scrutiny of 
individuals at risk of RA is a central part of 
this approach. At- risk populations have been 
identified based on the presence of a few well- 
recognised risk factors for the development 
of RA. These include a family history of RA, 
the presence of anticitrullinated protein anti-
bodies (ACPA) and certain musculoskeletal 
(MSK) symptoms. Within the different at- risk 
populations, data on several other risk factors 
have also been reported. These include 
different RA- related autoantibodies, imaging 
biomarkers, various clinical features and 
serological markers. Typically the risk factors 
collected vary in different observational 
studies and clinical trials. Consequently, the 
relative importance of these risk factors in 
Key messages
 ► Risk factors for arthritis development in rheumatoid 
arthritis (RA) are specific to the at- risk population.
 ► Serum anticitrullinated protein antibodies (ACPA) 
confer risk of RA in both asymptomatic and symp-
tomatic at- risk populations.
 ► Serum ACPA, clinical features and subclinical inflam-
mation on imaging should be considered as ‘core 
risk factors’ in individuals at risk of RA who have 
symptoms without clinical arthritis.
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at- risk populations can be difficult to interpret. There 
is also variation in which risk factors are used to select 
at- risk individuals for clinical trials.
The EULAR task force for conducting clinical trials 
and studies in individuals at risk of RA was convened to 
help align future work in this area through the provision 
of data- driven guidance and consensus. The task force 
agreed that population- specific core sets of risk factors 
should be stipulated for inclusion in future observa-
tional studies an clinical trials. The task force also felt 
that the frequency at which risk factor assessment should 
be repeated was an important question to be addressed. 
When defining the points to consider, participants of the 
EULAR task force were guided by the findings of this 
systematic literature review.
METHODS
An international multidisciplinary EULAR task force was 
convened to define points to consider for conducting clin-
ical trials and studies in individuals at risk of RA (co- con-
vened by KM and PE). At the first meeting (October 2019 
in Amsterdam, The Netherlands), the task force agreed 
on four key questions to be addressed by systematic litera-
ture reviews (SLR). A key question agreed and prioritised 
by the task force was: ‘In individuals at risk of rheumatoid 
arthritis (RA), is there core set of risk factors and how frequently 
should they be measured?’ The results of the corresponding 
SLR are presented in the current manuscript. Three 
other questions were also proposed and are addressed in 
the EULAR points to consider. However, the SLR on risk 
factors was deemed the most novel and contained the 
most data. The task force agreed that this SLR should be 
submitted for independent publication.
Study protocol
A literature search was carried out by two of the authors 
(KM and HS) and the expert health librarian (JK), 
following the Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses guidelines.1 For the literature 
search, relevant keywords determined by the librarian 
were used in Medline, Embase, PubMed and Central 
databases (searched from 1944 to October 2019); see 
online supplemental materials for full search strategy.
Inclusion criteria
We included studies, which demonstrated risk factors for 
arthritis development in individuals at risk of RA. Studies 
identifying risk factors in the following at- risk populations 
were eligible for inclusion: first- degree relatives (FDRs) 
of RA probands, indigenous North American popula-
tions, ACPA- positive individuals with/without MSK symp-
toms, seropositive arthralgia, clinically suspect arthralgia, 
undifferentiated arthritis (UA), palindromic rheumatism 
(PR). Abstracts published from January 2018 onwards 
were included. This was to ensure important recent data, 
yet to be published in full articles, were also included. 
Articles not published in English were excluded. Dupli-
cates were excluded. Meta- analyses were included but 
all other reviews and study protocols were excluded. 
Manually searched articles either from the references of 
selected manuscripts or identified by task force members 
could also be included.
Study selection
Studies retrieved from the searches were recorded on a 
central database. After removing conference abstracts 
(pre-2018), two investigators (KM and HS) inde-
pendently screened all titles. Abstracts of titles identi-
fied as potentially eligible for inclusion were then inde-
pendently assessed against the inclusion and exclusion 
criteria by the two investigators. Disagreements were 
settled by discussion between the two investigators and 
through discussion with a third investigator (ADM) 
where required. Discussions were held with the expert 
EULAR task force members to ensure additional relevant 
articles could also be identified (‘hand searched’).
Quality assessment
Quality assessment of studies was performed using the 
Newcastle- Ottowa Scale (NOS) for assessing the quality 
of non- randomised studies in meta- analysis.2 This was 
conducted by two of the investigators independently 
(ADM and DA- R). Any disagreement between the two 
investigators was resolved by a third independent inves-
tigator (KM). The NOS scores studies according to three 
items: selection, comparability and outcome. The final 
score (range 0–9) is a sum of the item scoring. The higher 
the score, the better the methodological quality and the 
lower risk of bias (RoB); studies with ≥6 stars were consid-
ered low RoB, those with 4 or 5 stars intermediate RoB 
and those with <4 stars at high RoB.
RESULTS
A total of 3854 articles were identified by the librarian 
search. A further 38 articles were identified by hand 
searches. No specific pattern was identified by the health 
librarian to explain why these articles were missed by the 
searches. After screening of titles, 176 abstracts and/or 
articles were reviewed and 96 articles were evaluated in 
detail (figure 1).
Articles identifying risk factors for the development 
of RA fell into one of two categories: (1) risk factors 
identified in prospective cohorts of individuals at risk of 
developing RA, or (2) risk factors for development of RA 
in the general population using retrospective (predom-
inantly case- control) studies. As the research question 
specifies risk factors in at- risk individuals, rather than the 
background population, articles which were in the first 
category were reviewed in detail.
Of the 96 articles evaluated in detail, 53 studies iden-
tifying risk factors in at- risk individuals were grouped 
according to the specific risk factor(s) identified in the 
study (table 1). All but two of the articles assessed were of 
high quality, that is, low RoB according to the NOS score 
(see online supplemental tables 1–4). Seven articles were 
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abstracts or letters and two were meta- analyses. These 
studies could not be assessed for RoB.
In these studies, risk factors are usually considered in 
a population- specific manner; for example, risk factors 
such as clinical features and subclinical inflammation 
on imaging are relevant in at- risk individuals with MSK 
symptoms but not in asymptomatic populations such as 
FDRs of RA probands.
ACPA and other autoantibodies
Thirteen articles specifically addressed ACPA and other 
autoantibodies as risk factors for arthritis development; 
10/13 had a low RoB and 2/13 had intermediate RoB. 
One article was a systematic review and meta- analysis.
Presence of RA- related autoantibodies, especially 
ACPAs, is the best characterised risk factor for arthritis 
development across the various at- risk populations, from 
those without symptoms through to those with early 
synovitis (table 2). Indeed, serum ACPAs were identified 
prior to the onset of arthritis in multiple seminal studies 
in this field.3–5 Considering asymptomatic populations 
(ie, without MSK symptoms), ACPA- positive individuals 
may be identified by screening in the general population 
or testing individuals with a heightened genetic risk of 
RA, that is, relatives of RA probands or Indigenous North 
American (INA) populations. There is good evidence 
that the latter groups are at higher risk of RA develop-
ment, whereas there are relatively few published longi-
tudinal data on arthritis development in ACPA- positive 
individuals screened from the general population. In a 
large Mexican cohort study, 819 healthy relatives (79% 
FDRs) of RA probands were followed prospectively for 5 
years to investigate for RA development.6 RA developed 
in 17 (2.1%) of the relatives, with a positive predictive 
value (PPV) of 64% when both anti- CCP and rheumatoid 
factor (RF) were present, and 58% when only anti- CCP 
was positive.6 In a recent longitudinal study of healthy 
Figure 1 Flow chart for article selection according to the Preferred Reporting Items for Systematic Reviews and Meta- 
Analyses guidelines.
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relatives of INAs with RA, in which autoantibody levels 
were serially measured, 4.8% developed inflammatory 
arthritis (IA) during follow- up. All were seropositive at 
IA onset. Thirty per cent of anti- CCP/RF double positive 
individuals developed IA. Interestingly, there was a 71% 
likelihood of an ACPA- positive state reverting to seroneg-
ative after 5 years.7 Furthermore, glycosylation of the IgG 
ACPA variable domain is present in FDRs of INAs with 
RA and is strongly associated with the future develop-
ment of RA (HR 6.1, 95% CI 1.5 to 25.2, p=0.01).8 Prior 
to the availability of ACPA testing, a large longitudinal 
study of >2000 INAs monitored bi- annually for 19 years 
revealed a highly significant association between RF level 
and RA development (p<0.01, controlling for age and 
sex).9 In a recent study of anti- CCP3- positive individuals 
identified by population screening at health fairs in the 
USA, 35 of 250 individuals who tested anti- CCP3 positive 
were recruited and followed longitudinally for mean of 
2.56 years.10 Forty per cent of these subjects developed 
IA.10
In at- risk individuals with MSK symptoms (seroposi-
tive arthralgia, clinically suspect arthralgia, ACPA posi-
tive with MSK symptoms), ACPA levels are also strongly 
associated with progression to IA. In a Dutch seroposi-
tive (anti- CCP + and/or RF+) arthralgia cohort, positive 
anti- CCP antibodies were associated with progression 
to IA (HR 6.0, 95% CI 1.8 to 19.8, p<0.01). Within 
anti- CCP- positive subjects, a high level of anti- CCP 
antibodies and/or the additional presence of IgM RF 
were further associated with progression to IA (HR 1.7, 
95% CI 1.1 to 2.5, p<0.01 and HR 3.0, 95% CI 1.4 to 6.9, 
p=0.01, respectively).11 In a subsequent study from the 
same group, higher anti- CCP levels were associated with 
a broader ACPA repertoire; patients recognising ≥2 of 5 
candidate ACPAs were at higher risk of IA development 
(p=0.04).12 In the Dutch clinically suspect arthralgia 
(CSA) cohort, where subjects are recruited based on their 
symptoms alone rather than serological status, anti- CCP 
positivity, but not RF or anti- carbamylated protein anti-
bodies (anti- CarP), was associated with development of 
IA (HR 5.1) in the multivariable analysis. However, in 
addition to anti- CCP positivity, lone RF positivity was also 
associated with IA development compared with seroneg-
ative individuals (HR 2.6).13 High anti- CCP level was also 
the strongest risk factor in two clinical prediction rules 
in Dutch seropositive patients with arthralgia14 and the 
Leeds cohort of ACPA- positive individuals with non- 
specific MSK symptoms.15 One study has demonstrated a 
positive association between serum anti- CarP antibodies 
and IA development in a cohort of anti- CCP/RF- positive 
patients with arthralgia (HR 1.6, p=0.02).16 This associa-
tion remained positive in the anti- CCP- positive subgroup 
(OR 2.2, p<0.01).
In patients with early UA, anti- CCP antibodies are also 
a strong risk factor for disease progression to RA.17–19 
Anti- CCP2 antibodies were the strongest predictive 
biomarker for progression to RA in a Japanese cohort 
of patients with UA, with other diagnostic biomarkers 
(including IgM RF and C reactive protein) adding 
minimal additional value.17 Anti- CCP2 antibodies were 
compared with anti- CCP3, RF and antimutated citrulli-
nated vimentin (MCV) antibodies in a prospective study 
of 625 patients with UA.19 Overall, anti- CCP2 antibodies 
had the highest PPV for RA development (67.1%), 
followed by anti- CCP3 (64%), RF (61.7%) and anti- MCV 
(56.3%).
In 376 Norwegian early arthritis clinic patients, the 
association between anti- CCP and RF levels and arthritis 
persistence was tested.18 Almost 50% of these patients 
had persistent arthritis at 1 year. Sensitivity/Specificity for 
persistent arthritis was 28%/95% for RF alone, 30%/95% 
for anti- CCP alone and 37%/92% for both autoanti-
bodies. Likelihood of persistent arthritis increased with 
increasing levels of both RF and anti- CCP.18
One important caveat when interpreting these studies 
is that patients were classified as UA based on failure to 
meet now outdated RA classification criteria. It is there-
fore likely that a significant proportion of these patients 
with UA would actually classify as RA based on contem-
porary criteria.20
Clinical features
Thirteen articles addressed clinical features as risk factors 
for arthritis development; 11/13 had a low RoB. Of the 
Table 1 Research articles identified by the literature search 












0 8 4 12
Subclinical 
inflammation on MRI
0 4 2 6
BMD 0 1 1 2
ACPA/RF/Other 
autoantibodies
6 4 3 13
Clinical features 0 4 9 13
Demographic 
features
0 1 0 1
Serum markers 1 2 1 4
Cellular markers 0 2 0 2
Genetic markers 0 1 1 2
Total 7 27 21 53
Fifty- three articles were identified: one article reported on both clinical 
and genetic risk factors; one article reported on both autoantibodies 
and serum markers.
*Including relatives of patients with RA.
ACPA, anticitrullinated protein antibodies; BMD, bone mineral density; 
MSK, musculoskeletal; PR, palindromic rheumatism; RA, rheumatoid 
arthritis; RF, rheumatoid factor; UA, undifferentiated arthritis.
 on O










pen: first published as 10.1136/rm






5Mankia K, et al. RMD Open 2021;7:e001768. doi:10.1136/rmdopen-2021-001768
Rheumatoid arthritis
Table 2 Articles reporting on RA- related autoantibodies as isolated risk factors in individuals at risk of RA




del Puente et al9 Healthy NAN 2712 RF Multiple:
bi- annually
RA development
Incidence of RA (cases per 1000 person- years) 
increased according to RF titre (p<0.001):
cases per 1000 person- years=2.4 (RF 




FDRs and relatives 
of RA probands
819 relatives 
of 252 RA 
probands
Relatives of RA 
probands
Once (BL) Development of RA
All relatives
Anti- CCP2+/RF + versus seronegative: HR 
52.5 (95% CI 19.1 to 144.1), p<0.01
Offspring versus other relatives
HR 3.1 (95% CI 1.2 to 8.1)
Gan et al52 Anti- CCP3- 
positive individuals 
screened from the 
general population
35 Anti- CCP3 Once (BL) Development of IA
Anti- CCP3: 14/35 (40%) of anti- CCP3 + 
individuals developed IA at 2.56 years follow- 
up











Number of different autoantibodies present:
one antibody: OR 12 (95% CI 6 to 21)
two antibodies: OR 30 (95% CI 11 to 83)
three antibodies: OR 112 (95% CI 6 to 2122)
Tanner et al7 Unaffected relatives 
of NAN RA- 















FDRs of patients 
with RA, in NANs
126 IgG ACPA 
V‐domain 
glycosylation
  Development of RA
IgG ACPA variable‐domain glycosylation:
HR=6.07 (95% CI 1.46 to 25.2, p=0.013)
MSK symptoms 
without arthritis









Once (BL) Development of IA
Compared with RF:
anti- CCP: HR 6.0 (95% CI 1.8 to 19.8); p=0.004
In anti- CCP + only:
anti- CCP+/IgM RF+: HR 3.0 (95% CI 1.4 to 
6.9), p=0.01.
High anti- CCP level: HR 1.7; (95% CI 1.1 to 
2.5), p=0.008











Once (BL) Development of IA
Recognition of 2–5 additional citrullinated 
peptides: HR 1.7 (95% CI 0.93 to 3.16), p=0.08
Shi et al16 Seropositive 
arthralgia (anti- 
CCP2 and/or RF)
340 Anti- CarP Ab Once (BL) Development of IA
Anti- CarP antibodies: HR=1.56 (95% CI 1.06 
to 2.29), p=0.003.
In anti- CCP + subgroup only:
anti- CarP antibodies: HR=2.23 (95% CI 1.31 to 
3.79), p=0.003
Ten Brinck et al13 CSA 241 ACPA, RF and 
anti- CarP Ab
Once (BL) Development of IA
Anti- CCP2: HR=5.1 (95% CI 2.0 to 13.2)
RF: 2.0 (95% CI 0.81 to 4.9)
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two articles without low RoB, one article was an abstract 
and one was a systematic review and meta- analysis.
Clinical features have not been well characterised 
in at- risk populations who do not have MSK symptoms 
(ie, FDRs and INA populations). A range of clinical 
features related to the MSK system have been charac-
terised in ACPA- positive individuals with MSK symp-
toms, patients with seropositive arthralgia, patients with 
CSA and patients with early arthritis (ie, UA and PR) 
(table 3). Whether non- MSK symptoms, for example, 
fatigue, are relevant to disease progression will be an 
important area for future research. Composite risk 
prediction tools incorporating multiple clinical features 
have been reported for seropositive arthralgia14 and 
ACPA- positive individuals with MSK symptoms.15 The 
Dutch risk prediction tool was based on an analysis of 
374 patients with seropositive arthralgia, 254 (68%) of 
whom were anti- CCP positive. One hundred thirty- one 
(35%) patients developed arthritis after a median of 12 
months. In the multivariate Cox regression analysis, six 
clinical MSK features were associated with arthritis devel-
opment: duration of symptoms <12 months, intermittent 
symptoms, location of symptoms in the upper and lower 
extremities, visual analogue scale (VAS) pain ≥50, early 
morning stiffness (EMS) ≥1 hour, swollen joints reported 
by the patient. Of these, VAS pain ≥50 had the strongest 
association with progression (HR 2.3) and was given two 
points in the risk score while all other clinical features 
were given one point.14 A subsequent UK risk predic-
tion tool (Leeds CCP cohort) was based on a cohort of 
100 anti- CCP- positive individuals with non- specific MSK 
symptoms, of whom 50 developed arthritis after a median 
of 7.9 months.15 In this study, only two clinical features 
were associated with arthritis development, tenderness 
of small joints and EMS (≥30 min and ≥60 min). Pain 
VAS ≥50, intermittent symptoms and symptoms in the 
upper and lower extremities were not predictive.15 In 
both risk prediction tools, autoantibody status had a far 
stronger association with arthritis development than any 
clinical feature.14 15 The EULAR definition of arthralgia 
suspicious for progression to RA (ie, the accepted case 
definition of CSA) is a set of six clinical features (and 
one genetic factor) deemed by rheumatologists to repre-
sent an increased risk for arthritis development.21 These 
include symptoms duration <1 year, metacarpophalan-
geal (MCP) joint symptoms, EMS ≥60 min, most severe 
symptoms in morning, difficulty making a fist, positive 
MCPJ squeeze test. This definition was subsequently vali-
dated in two independent cohorts of patients with CSA 
from Leiden (The Netherlands) and Umea (Sweden).22 
Recruitment into these cohorts preceded the EULAR 
definition. Individuals meeting criteria for a positive defi-
nition of CSA (≥3 of the above listed factors present) had 
an increased risk of developing arthritis compared with 
definition- negative patients (HR 2.1, 95% CI 0.9 to 4.7), 
although statistical significance was not reported. The 
sensitivity was 84% and the PPV was 30%.22
The majority of published data on clinical features as 
risk factors in at- risk individuals are reported in patients 
with early clinical arthritis, classifying as UA based on 
criteria that precede 2010 RA classification criteria.23–30 
The clinical parameters used in these studies are 
summarised in table 3.
In patients with PR, clinical features have also been 
demonstrated to be risk factors for RA development. In a 
retrospective review of 127 Spanish patients with PR, 36 
Study Population studied Cohort size Risk factor
Frequency 
assessed Main outcome
Kudo- Tanaka et 
al17
Recent- onset (<2 
years) UA (arthritis 
in ≥2 joints not 







Once (BL) RA development
(PPV, NPV and diagnostic accuracy) anti- 
CCP2: 65.2%, 97.2%, 91.7%, respectively;
IgM RF: 34.1%, 95.6%, 76.3%, respectively;
CARF: 30.2%, 97.5%, 70.5%, respectively;
MMP3: 25.0%, 91.5%, 69.0%, respectively
van der Linden 
et al19
Early (<2 years) UA 625 Anti- CCP2
Anti- CCP3
Anti- MCV





Mjaavatten et al18 UA (≥1 clinically 






Once (BL) Development of persistent IA
Anti- CCP: OR 3.567 (95% CI 1.572 to 8.094)
IgM RF: OR 2.716 (95% CI 1.189 to 6.202)
Anti- CCP+/RF+: OR 7.948 (95% CI 2.659 to 
23.752)
HR/OR and 95% CIs have been reported where available.
+, positive; Ab, antibodies; ACPA, anticyclic citrullinated peptide antibodies; BL, baseline; CARF, anti- agalactosyl IgG antibodies; 
CarP, carbamilated protein; CCP, cyclic citrullinated peptide; CCP2, second- generation anti- CCP Ab; CCP3, third- generation anti- 
CCP Ab; CSA, clinically suspect arthralgia; FDRs, first- degree relatives; IA, inflammatory arthritis; MCV, mutated citrullinated vimentin; 
MMP-3, matrix metalloproteinase 3; NAN, native American nations; NPV, negative predictive value; PPV, positive predictive value; RA, 
rheumatoid arthritis; RF, rheumatoid factor; UA, undifferentiated arthritis.
Table 2 Continued
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(28%) had subsequently developed RA and early involve-
ment of the wrist and proximal interphalangeal (PIP) 
joints was associated with this progression.31 However, the 
presence of RF was more strongly associated with devel-
opment of RA compared with any clinical factors and 
this study predated the routine use of ACPA assays. In a 
subsequent Japanese cohort study, PIP joint involvement 
was again associated with arthritis development (OR 8.2). 
However, anti- CCP antibodies were much more predic-
tive than clinical factors (OR 46.7).32
Imaging markers
Eighteen articles specifically addressed imaging markers 
as risk factors for arthritis development; 13/18 had a low 
RoB. The five articles without low RoB were abstracts, 
therefore RoB was not applicable.
In at- risk individuals with MSK symptoms, including 
anti- CCP + individuals with MSK symptoms and patients 
with seropositive arthralgia, joint abnormalities on high- 
resolution ultrasound (US) are associated with arthritis 
development (table 3). US abnormalities are also predic-
tive of disease progression in patients with UA (table 4). 
In a UK cohort of 136 anti- CCP- positive individuals with 
MSK symptoms, US features were predictive of arthritis 
development at both joint and patient level.33 US 
erosions and grey- scale (GS) synovitis were both predic-
tive of arthritis at patient level, although intra- articular 
power Doppler (PD) signal had the highest predictive 
value (HR 3.7, 95% CI 2.0 to 6.9, p<0.01). There was an 
even stronger association with progression at joint level; 
PD grade ≥2 had an HR 31.3, 95% CI 15.6 to 62.9, p<0.01. 
In the same cohort, US scans acquired at multiple time 
points have been analysed to identify predictors of disease 
progression. In 44 subjects who had 3 serial US scans, 
those patients who developed arthritis had an increase 
in US inflammation (ie, total PD score) between scans 
2 and 3 (preprogression and progression to arthritis) 
compared with the corresponding time points in non- 
progressors, suggesting US inflammation is a late feature 
which heralds the imminent onset of clinical arthritis.34 
In a subsequent analysis of 307 subjects, the frequency 
of US PD at patient level (ie, number of joints affected) 
increased in the 12 months prior to arthritis develop-
ment.35 In a Dutch seropositive arthralgia cohort, US 
changes (ie, PD signal, GS synovitis, erosions) were asso-
ciated with arthritis development at joint level but not 
patient level, although the US protocol contained fewer 
joints compared with the UK cohort studies.36 In a subse-
quent study, GS synovitis (grade ≥2) was associated with 
the development of arthritis and its timing at patient level 
(metatarsophalangeal (MTP) joints excluded); HR 3.4. 
Interestingly, there was no positive association with PD 
in this study and the predictive capacity of US was higher 
in individuals at higher risk of arthritis, based on a clin-
ical prediction rule based on this cohort.14 37 These data 
further emphasise the predictive utility of US in higher 
risk individuals with MSK symptoms. In a Swedish cohort 
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Table 4 Articles reporting imaging findings alone as risk factors in individuals at risk of RA
Study Population
Cohort 
size Risk factor Frequency Outcome
Ultrasound alone
MSK symptoms without arthritis





192 US PD signal (joint level) BL Development of IA
OR=2.9 (95% CI 4.65 to 360)
Nam et al33 Anti- CCP + with 
non- specific MSK 
symptoms
136 US PD signal (patient level)
US BE (patient level)
USGS ≥2 (patient level)
BL Development of IA
US PD signal: HR 3.7 (95% CI 2.0 
to 6.9), p<0.001
US BE: HR 2.9 (95% CI 1.7 to 
5.1), p<0.001
US GS ≥2: HR 2.3 (95% CI 1.0 to 
4.9), p=0.038
Zufferey et al40 Anti- CCP- negative 
patients with 
arthralgia and no 
synovitis
80 US synovitis (SONAR score) BL Progression to RA
OR=7.4 (95% CI 1.19 to 42.8), 
p=0.02





163 US GS ≥2 (excluding MTP joints)
(patient level)
BL Development of IA
HR=3.4 (95% CI 1.6 to 6.8), p<0.01
Pentony et al34 Anti- CCP + with 
non- specific MSK 
symptoms
44 US total PD score in the wrists, 





54.5% progressors had increased 
PD signal score longitudinally vs 
9.1% non- progressors
Kisten et al38 Anti- CCP + with 




66 US TSV (patient level) BL or FU visits Development of IA




Anti- CCP + with 




66 Combined US- TSV on US (patient 
level) and positive HLA- SE
BL
Development of IA
HR=4.9 (95% CI 1.5 to 16), p=0.01
Duquenne et 
al35
Anti- CCP + with 
non- specific MSK 
symptoms















50 US GS score ≥3, PD signal ≥1, ≥1 
BE
BL Development of persistent arthritis
Probability increased from 34% to 
94%
Filer et al42 UA—early 
synovitis of ≥1 
joint and symptom 
duration ≤3M
58 PD 10 index: summed PD grades 
of MCP joints 2–3, wrists and MTP 
joints 2–3
BL Development of RA
PD 10 index combined with Leiden 
prediction score: AUC 0.962, 






joint and symptom 
duration ≤3M
107 US digital flexor TSV
Positive PD signal in MCP3
BL Development of RA
OR=4.066 (95% CI 1.444 to 
11.444), p=0.008
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clinical or US synovitis, US tenosynovitis was associated 
with arthritis development (RR 3.0, 95% CI 1.8 to 4.8, 
p<0.01).38 39
In seronegative at- risk individuals with arthralgia, US 
synovitis (Swiss SONAR criteria positive) is also asso-
ciated with arthritis development.40 Furthermore, in 
seronegative patients with early UA, US synovitis and 
erosions were associated with development of persistent 
arthritis.41 GS synovitis in the wrists and MCP joints and 
PD signal in the MTP joints were all associated with devel-
opment of RA in a UK cohort of patients with very early 
UA.42 In a subsequent analysis of 107 patients with UA by 
Study Population
Cohort 
size Risk factor Frequency Outcome
Kleyer et al44 ACPA- positive at- risk 
individuals
20 MRI TSV at ≥2 sites BL Development of RA
5/5 (100%) of individuals who 





CSA 150 Subclinical MRI inflammation BL Development of IA
HR=5.07 (95% CI 1.77 to 14.50), 
p=0.002
Boer et al63 Patients with CSA 






‘corrected’ for MRI abnormalities in 
healthy individuals
BL ‘Corrected’ versus ‘uncorrected’ 
MRI inflammation
Development of IA at 12 months
Accuracy 60% (95% CI 54 to 67) vs 
32% (95% CI 26–38)
AUC 0.71 vs 0.55
Fulfilment of 1987 RA criteria at 12 
months
Accuracy 44% (95% CI 38 to 51) vs 
22% (95% CI 17 to 29)
AUC 0.65 vs 0.52
Hunt et al45 Anti- CCP + 
individuals with 





BL Development of IA
HR=4.02 (95% CI 1.91 to 8.44), 
p=0.002
HR=5.09 (95% CI 1.93 to 13.44), 
p=0.006
HR=2.69 (95% CI 1.14 to 
6.34), p=0.059
Early clinical arthritis
Navalho et al49 Untreated recent 
onset (<1 year) 
polyarthritis
32 MRI ECU TSV
MRI FT2 TSV
MRI synovitis of the radioulnar joint
BL Development of RA
OR=3.21 (95% CI 1.09 to 9.40), 
p=0.03
OR=9.6 (95% CI 1.17 to 78.93), 
p=0.03
OR=8.79 (95% CI 1.02 to 75.63), 
p=0.04
Navalho et al47 Untreated recent 
onset (<1 year) 
undifferentiated 
polyarthritis
4 MRI carpal joint synovitis
MRI flexor tendon TSV
MRI global joint and tendon count
Global MRI and US scores
BL Development of RA
OR=3.64 (95% CI 1.19 to 11.84), 
p=0.032
OR=5.09 (95% CI 1.62 to 16.05), 
p=0.005
OR=2.77 (95% CI 1.249 to 6.139), 
p=0.012
AUC=0.959 and=0.853, respectively, 
p<0.05
Dakkak et al48 UA (arthritis in ≥1 
joint, symptom 
duration <2 years)
123 MRI TSV in feet adjusted for BME 
and synovitis of the foot
MRI TSV in feet adjusted for CRP 
and swollen joint count
MRI TSV in hands independent of 
BME and synovitis
BL Development of RA
OR=3.29 (95% CI 1.03 to 10.53)
OR=2.14 (95% CI 0.77 to 5.95)
OR=3.99 (95% CI 1.64 to 9.69)
HR/OR and CIs have been reported where available.
+, positive; A, abstract only; ACPA, anticyclic citrullinated peptide antibodies; AUC, area under the curve; BE, bone erosions; BL, baseline; BME, 
bone marrow oedema; CCP, cyclic citrullinated peptide; CRP, C reactive protein; CSA, clinically suspect arthralgia; ECU, extensor carpi ulnaris; 
FDRs, first- degree relatives; FT, flexor tendons; FU, follow- up; GS, grey scale; IA, inflammatory arthritis; M, months; MCPs, metacarpophalangeal 
joints; MSK, musculoskeletal; MSUS, musculoskeletal ultrasound; MTPs, metatarsophalangeal joints; PD, power Doppler; PPV, positive predictive 
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the same group, US tenosynovitis was frequently identi-
fied and US finger flexor tenosynovitis was predictive of 
RA development (OR 3.1, 95% CI 1.05 to 9.05, p=0.04).43
In both ACPA- positive individuals with MSK symp-
toms and patients with CSA, subclinical inflammation on 
MRI has been associated with arthritis development44–46 
(table 4). In both populations, MRI tenosynovitis was 
the most prevalent MRI abnormality and also the most 
strongly associated with arthritis development. In a study 
of 150 Dutch patients with CSA, 31% of patients with 
baseline subclinical MRI inflammation (either synovitis, 
osteitis or tenosynovitis) had developed clinical arthritis 
at 1 year (71% of ACPA- positive patients with CSA with 
MRI inflammation had developed arthritis). MRI tenosy-
novitis was the only MRI feature independently associated 
with arthritis development in the multivariable anal-
ysis (HR 8.4, 95% CI 3.4 to 20.8, p<0.01).46 Similarly, at 
patient level, MRI tenosynovitis was the only MRI feature 
associated with arthritis development in a UK cohort of 
98 ACPA- positive individuals with MSK symptoms (HR 
4.02, 95% CI 1.9 to 8.4, p<0.01).45
MRI findings in patients with UA are also associated 
with disease progression and specifically RA develop-
ment.47 48 In a small study of patients with recent- onset 
polyarthritis, MRI tenosynovitis of the finger flexor 
tendons and extensor carpi ulnaris, and synovitis of 
the radioulnar joint were associated with progression 
to RA.49 In this study, MRI was more sensitive than US 
for joint and tendon inflammation. In a subsequent 
study comparing MRI and US in the same cohort, MRI 
was more accurate for predicting RA development.47 In 
patients with UA, MRI tenosynovitis in the foot was also 
associated with development of RA, independent of bone 
marrow oedema (BME) and synovitis (OR 3.3, 95% CI 
1.0 to 10.5).48 However, in this study adding MRI of the 
foot did not improve the predictive accuracy compared 
with MRI of the hands alone.
Serum markers
Four articles specifically addressed serum markers as risk 
factors for arthritis development. Three of these articles 
had low RoB. The one article which did not have a low 
RoB was a research letter, therefore RoB could not be 
formally assessed.
The vast majority of published work on serum 
biomarkers as risk factors in at- risk individuals relates 
to autoantibodies. There are relatively few data on 
other serum biomarkers (table 5). In a Dutch seroposi-
tive arthralgia cohort, the serum inflammatory protein 
14-3- 3eta was detectable up to 5 years before the onset of 
clinical arthritis and was present more frequently and at 
higher levels in those who developed arthritis compared 
with those who did not.50 However, it was not clear 
from this study whether 14-3- 3eta levels could predict 
arthritis onset independently of autoantibodies. Serum 
dyslipidaemia was also investigated in the same cohort; 
of several lipid markers measured, lower baseline levels 
of apolipoprotein A1 were associated with an increased 
risk of arthritis development, even after adjustment for 
anti- CCP status (HR 0.5, 95% CI 0.3 to 0.9).51
In a small prospective cohort (n=35) of at- risk individ-
uals identified by screening for anti- CCP3 antibodies at 
health fairs, increased levels of docosapentaenoic acid (a 
n-3 fatty acid) in red blood cells appeared to be protec-
tive for the development of IA (HR 0.5, 95% CI 0.3 to 
1.0).52
Cellular markers
Two articles specifically addressed cellular markers as risk 
factors for arthritis development. Both had low RoB.
Circulating T- cell and B- cell biomarkers appear to be 
risk factors for arthritis development in at- risk individ-
uals, although relatively few data have been published. 
In a UK cohort of anti- CCP positive individuals with MSK 
symptoms, frequencies of circulating T- naïve and T- reg 
cells were reduced, while inflammation- related cells were 
increased compared with controls.53 The presence of 
two or more T cell abnormalities had high specificity for 
arthritis development and a prediction model combining 
clinical factors and T- cell subsets performed better than 
clinical factors alone (AUC 0.8, 95% CI 0.7 to 0.9).53 In 
patients with seropositive arthralgia, the expansion of 
B- cell receptor clones (ie, presence of dominant clones) 
was associated with arthritis development. In both a test 
and validation cohort, the presence of ≥5 dominant B- cell 
clones was independently associated with arthritis devel-
opment (Relative Risk 6.3, 95% CI 2.7 to 15, p<0.01).54 
Interestingly, when at- risk individuals developed arthritis, 
the dominant B- cell receptor clones appeared in synovial 
tissue but disappeared from peripheral blood, suggesting 
migration into target tissue in the at- risk phase.
Genotype, gene expression and other markers
Two articles specifically addressed genotype and gene 
expression as risk factors for arthritis development. 
Two articles addressed bone mineral density and one 
addressed demographic features. All of these articles 
were deemed to have a low RoB.
There is very limited published work on genetic 
markers (genotype or gene expression) as independent 
risk factors for arthritis in individuals at risk of RA. In the 
Leeds cohort of anti- CCP- positive individuals with MSK 
symptoms, one or more copies of HLA DR shared epitope 
(SE) alleles was associated with development of clinical 
arthritis (HR 2.5, 95% CI 1.0 to 5.9). Consequently, HLA 
DR SE was included in the Leeds risk prediction tool.15 In 
a UK study of patients with very early UA, synovial mRNA 
expression of 117 cytokines was measured in synovitic 
joints. Higher mRNA levels of the inflammatory chemo-
kines CXCL4 and CXCL7 were identified in individuals 
with very early RA (ie, in the early phase of persistent 
arthritis) compared with those with resolving arthritis.55
Two Dutch studies have demonstrated that bone 
mineral density (BMD) loss measured by X- ray is associ-
ated with disease progression, both in patients with CSA 
and patients with early UA.5657 In 108 patients with CSA, 
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BMD loss was associated with total MRI inflammation 
scores, and both factors were independently associated 
with arthritis development.56 In a separate cohort of 101 
patients with UA, highly elevated BMD loss (≥2.5 mg/
cm2/month) was associated with RA development (OR 
6.1, 95% CI 1.2 to 29.2). Of the various demographic 
Table 5 Other risk factors which have been reported in individuals at risk of developing RA
Study Population
Cohort 
size Risk factor Frequency Outcome
BMI   
Deane et al59 ACPA + subjects 
without arthritis 
(some FDRs, some 
clinic patients and 
some health fares)
86 Those with incident RA 
had higher BMI (p=0.03)
BL Development of IA
Higher BMI in progressors 
versus non- progressors (32 vs 
27), p=0.03
Serum/Cellular/Genetic   
Asymptomatic
Gan et al52 Anti- CCP3 + 
individuals without 









HR=0.52 (95% CI 0.27 to 0.98)
MSK symptoms without arthritis





144 14-3- 3eta BL Development of IA
RR=2.5 (95% CI 1.2 to 5.6), 
p=0.02





348 Lower ApoA1 level BL Development of IA
HR 0.52 (95% CI 0.29 to 0.92)
Rakieh et al15 Anti- CCP + 
individuals with 
non- specific MSK 
symptoms
100 HLA DR shared epitope BL Development of IA
HR=1.84 (95% CI 1.02 to 3.32)
Hunt et al53 Anti- CCP + 
individuals with 
non- specific MSK 
symptoms
103 Combined clinical and T- 
cell subset parameters
BL and repeated 
at 1 year
Development of IA
AUC 0.79. PPV 60% and NPV 
95%
Early clinical arthritis
Jacobsen et al64 Early (<2 years) 
polyarthritis
68 Homozygous for MBL 
variant alleles
BL Development of RA
OR 4.7 (95% CI 1.1 to 19), 
p=0.02
Yeo et al55 UA—early 
synovitis ≥1 joints 
with symptoms ≤3 
months
48 Synovial mRNA and 
protein expression of 
CXCL4 and CXCL7
BL assessment Development of RA at 18 
months
Progressors versus non- 
progressors
Increased expression (trend) in 
progressors
BMD
Mangnus et al56 CSA 108 BMD loss BL and one 
subsequent visit
Development of IA
HR 6.1 (95% CI 1.7 to 21.4), 
p=0.005
de Rooy et al57 Early UA 125 Highly elevated BMD loss 
(>2.5 mg/cm2/month)
BL and 6 
months
Development of RA
OR 6.1 (95% CI 1.24 to 29.24)
HR/OR and CIs have been reported where available.
+, positive; ;A, abstract only; ACPA, anticyclic citrullinated peptide antibodies; ApoA1, apolipoprotein A1; AUC, area under the curve; BCR, 
B cell receptor; BL, baseline; BMD, bone mineral density; BMI, body mass index; CCP, cyclic citrullinated peptide; CRP, C- reactive protein; 
CXCL, C- X- C motif ligand; FA, fatty acid; FDRs, first- degree relatives; FU, follow- up; HLA- SE, human leucocyte antigen- shared epitope; 
hs- CRP, high- sensitive C reactive protein; M, months; MBL, mannose binding- lectine; MCP‐1, monocyte chemotactic protein 1; MSK, 
musculoskeletal; NAN, native American nations; NPV, negative predictive value; PPV, positive predictive value; RA, rheumatoid arthritis; RF, 
rheumatoid factor; ROC, receiving operating characteristics; RR, relative risk.
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factors measured in at- risk cohorts, elevated body mass 
index (BMI) has been demonstrated to be associated 
with progression to arthritis in cohorts of patients with 
seropositive arthralgia and ACPA- positive individuals 
(from health fairs, clinic patients and some FDRs).58 59 In 
83 ACPA- positive individuals recruited from health fairs, 
rheumatology clinics and FDRs, BMI was higher in the 
10 individuals who progressed to arthritis compared with 
those that did not (32 vs 27, p=0.03).59 In an early analysis 
of the Dutch seropositive arthralgia cohort, elevated BMI 
and smoking history were both independently associated 
with the development of arthritis in the 15/55 (27%) of 
individuals who progressed. Of the two, smoking had the 
stronger association with arthritis (HR 9.6, 95% CI 1.3 to 
73, p=0.03 vs HR 5.6, 95% CI 1.3 to 25, p=0.02).58
Repeat assessment of risk factors
The large majority of the prospective studies described 
have evaluated risk factors for arthritis development at 
only the baseline time point (ie, the first assessment). 
There is, therefore, insufficient published data to indi-
cate the optimum frequency at which risk factors should 
be measured in at- risk individuals, and whether and how 
specific risk factors may fluctuate over time. This is an 
important area for future research. The limited studies 
that have assessed risk factor(s) at multiple time points 
highlight the unique insights which may be derived from 
this approach; sequential US assessments in ACPA- positive 
individuals with MSK symptoms suggest the development 
of US inflammation is a relatively late event, which occurs 
when clinical arthritis is imminent.34 35 Furthermore, 
serial autoantibody assessments in FDRs of INAs suggest 
that in many individuals, ACPA/RF resolve over time 
and individuals become seronegative.7 The stability and 
timing of other risk factors in relation to the development 
of arthritis in at- risk individuals has not been reported.
DISCUSSION
This SLR was performed to address a key question raised 
by the EULAR task force for conducting clinical trials 
and studies in individuals at risk of RA. Where relevant, 
SLRs addressing other questions raised by the taskforce 
will be published separately. There is significant interest 
in the study of risk factors in at- risk individuals. Multiple 
risk factors have now been reported, across multiple 
biomarker modalities and in different at- risk populations. 
A key ambition of the task force was to provide evidence- 
based guidance on a ‘core set’ of risk factors for each 
at- risk population, so that investigators could include 
these in future observational studies and clinical trials. 
Of note, certain risk factors for RA have been identified 
in large case- control studies undertaken in the wider 
background population, but have not been identified in 
populations of at- risk individuals. A detailed discussion of 
all such risk factors was outside the scope of this review.
Across all at- risk populations, the most well- described 
risk factor for arthritis development is the presence of 
serum RA- related autoantibodies, in particular ACPA. 
The level of ACPA, and its combination with RF, has been 
consistently demonstrated to predict arthritis develop-
ment in at- risk individuals across the continuum, from 
FDRs through to patients with UA. Imaging abnormal-
ities (mainly on MRI and US) appear to be significant 
Table 6 Core risk factors for development of arthritis in individuals at risk of RA according to population
At- risk population Subpopulations Core risk factors for arthritis
Asymptomatic at- risk 
individuals
Relatives of RA probands   Serum ACPA level±RF
Indigenous at- risk populations
ACPA + individuals identified by 
population screening
MSK symptoms without 
arthritis
ACPA + with MSK symptoms Serum ACPA level±RF
MSK symptoms
Subclinical joint inflammation on US
Subclinical joint and tendon inflammation on MRI
ACPA+/RF + with arthralgia Serum ACPA level±RF
MSK symptoms
Subclinical joint inflammation on US
Clinically suspect arthralgia Serum ACPA level±RF
MSK symptoms
Subclinical joint and tendon inflammation on MRI
Early clinical arthritis Palindromic rheumatism Serum ACPA level±RF
MSK symptoms
Undifferentiated arthritis Serum ACPA level±RF
MSK symptoms
Subclinical joint inflammation on US
Subclinical joint and tendon inflammation on MRI
ACPA, anticitrullinated protein antibodies; MSK, musculoskeletal; RA, rheumatoid arthritis; RF, rheumatoid factor; US, ultrasound.
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risk factors for arthritis in symptomatic at- risk populations 
(ie, seropositive arthralgia, ACPA- positive individuals 
with MSK symptoms, CSA and UA). This includes recent 
MRI studies, which highlight tenosynovitis as a risk factor 
for disease progression. Of note, imaging abnormalities 
have not been well studied in asymptomatic at- risk popula-
tions (ie, FDRs, genetically predisposed individuals and 
ACPA + subjects screened from the general population) 
and further investigation is required. A range of clinical 
features also confer increased risk of arthritis in symp-
tomatic at- risk populations; the majority of published 
data have been in UA cohorts and many describe clin-
ical features as part of composite risk prediction tools, 
which also include autoantibodies. In at- risk individuals 
with MSK symptoms but without clinical arthritis, clin-
ical features which indicate inflammatory type symptoms 
(eg, prolonged EMS duration) have been reported as 
risk factors for arthritis in several populations, and form 
important components of risk prediction tools (table 6). 
The significance of clinical symptoms in at- risk individ-
uals without MSK symptoms has not been well studied.
While there are data suggesting other serum and 
cellular biomarkers may be associated with arthritis devel-
opment in at- risk populations, these are far fewer and 
largely demonstrated in single studies without validation 
in other cohorts. Without further evidence, these would 
not yet be appropriate to consider as ‘core’ risk factors. 
The EULAR task force agreed a research agenda, which 
included several open questions related to risk factors in 
at- risk populations which should be addressed by future 
research (see ‘Research agenda’ section).
The strengths of this SLR include an expert librari-
an- led search and the review of all titles, relevant abstracts 
and papers by two investigators. We also benefitted from 
the expert knowledge of the EULAR task force; some 
additional relevant manuscripts, which were not identi-
fied in the literature search, have been included in the 
SLR. The risk of important articles being missed is there-
fore low. One limitation is that the SLR is restricted to 
narrative review as there was significant heterogeneity in 
the data and populations were not comparable between 
studies.
The identification of specific risk factors in at- risk popu-
lations is critical both on a pragmatic level, to improve 
the precision of risk prediction, and also on a scientific 
level, to improve our understanding of the pathobiology 
of RA. This SLR has served to bring together this infor-
mation and has informed the guidance provided in the 
EULAR points to consider in this key area.
RESEARCH AGENDA
 ► Do the risk factors that drive RA autoimmunity and 
disease progression vary according to the ethnicity or 
geography of the population?
 ► Which biomarkers/risk factors change as individuals 
progress to IA?
 ► In individuals at risk of RA what is the sequence and 
timescale of the changes in biomarkers/risk factors?
 ► How frequently should we re- assess an individual’s 
risk and is this subpopulation- dependent?
 ► Should interventions be personalised to an individ-
ual’s risk factors? For example, smoking cessation, 
treatment of periodontitis, weight loss?
 ► In those at high risk, should multimodal interven-
tion be considered according to risk factors? For 
example, immunomodulation combined with peri-
odontal therapy/smoking cessation/weight loss as 
appropriate.
 ► Does reduction in one or more risk factors reduce the 
likelihood of progression?
 ► Can the quantification of an individual’s risk be 
improved, and risk scores validated?
 ► Should individuals with mucosal inflammation/
dysbiosis (periodontal, lung or gut) with or without 
genetic predisposition or serum autoantibodies be 
considered as an at- risk group?
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